SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZTC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: HIA who wrote (568)10/22/1998 2:32:00 AM
From: Andrew H  Read Replies (1) of 752
 
GZTC has tremendous potential but really shot themselves in the foot with the floorless convertible preferred. Still, the maximum dilution from that offering is about 25%. AT111 should be worth one hell of a lot more of that if it passes P3.

I do not understand how they can go into P3 with a transgenic product. My understanding was that the FDA required all 3 phases of trials with a transgenic product, that it was not enough to show chemical identity with an already existing drug.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News